Inhibrx Biosciences (INBX) Retained Earnings (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Retained Earnings data on file, last reported at -$246.2 million in Q4 2025.

• On a quarterly basis, Retained Earnings fell 131.98% year-over-year to -$246.2 million in Q4 2025; TTM through Dec 2025 was -$246.2 million, a 131.98% decrease from a year earlier, with the FY2025 full-year figure at -$246.2 million, down 131.98% from the prior year.
• Retained Earnings for Q4 2025 stood at -$246.2 million, down from -$213.4 million in the prior quarter.
• Over the last five years, Retained Earnings for INBX reached as high as $657.2 million in Q4 2023 and fell as low as -$246.2 million in Q4 2025.
• Historically, Retained Earnings has averaged $45.5 million across 3 years, with a median of -$82.2 million in 2024.
• On a YoY basis, Retained Earnings climbed as much as 5.51% in 2025 and fell as far as 266.04% in 2025.
• Year by year, Retained Earnings stood at $657.2 million in 2023, then sank by 116.15% to -$106.1 million in 2024, then slumped by 131.98% to -$246.2 million in 2025.
• Per Business Quant data, the three most recent Retained Earnings figures were -$246.2 million in Q4 2025, -$213.4 million in Q3 2025, and $246.7 million in Q2 2025.